Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Italian (Borsa Italiana) Healthcare Sector Analysis

UpdatedAug 30, 2026
DataAggregated Company Financials
Companies18
  • 7D0.6%
  • 3M5.7%
  • 1Y-4.9%
  • YTD5.0%

In the last week, Healthcare has been flat. Unfortunately though, the industry is down 4.9% over the past 12 months. Looking forward, earnings are forecast to grow by 12% annually.

Sector Valuation and Performance

Has the Italian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 30 Aug 2026€22.1b€9.2b€1.1b23x20.4x2.4x
Tue, 28 Jul 2026€21.3b€9.1b€1.0b23.4x20.4x2.3x
Thu, 25 Jun 2026€21.0b€9.1b€1.0b25.9x20.2x2.3x
Sat, 23 May 2026€20.3b€9.1b€1.0b23.4x19.5x2.2x
Mon, 20 Apr 2026€19.9b€9.1b€1.0b22.4x19.1x2.2x
Wed, 18 Mar 2026€18.3b€8.8b€857.2m19.4x21.3x2.1x
Fri, 13 Feb 2026€21.0b€8.8b€886.9m20.8x23.6x2.4x
Sun, 11 Jan 2026€21.3b€8.8b€886.9m21.3x24x2.4x
Tue, 09 Dec 2025€20.4b€8.8b€886.9m19.5x23.1x2.3x
Thu, 06 Nov 2025€21.9b€8.8b€886.0m20.9x24.7x2.5x
Sat, 04 Oct 2025€22.9b€8.8b€895.5m20.8x25.6x2.6x
Mon, 01 Sep 2025€23.1b€8.7b€902.9m20x25.6x2.7x
Wed, 30 Jul 2025€24.7b€8.6b€941.3m20.5x26.2x2.9x
Fri, 27 Jun 2025€23.8b€25.2b€985.5m19.9x24.2x0.9x
Sun, 25 May 2025€22.7b€25.2b€985.5m19.3x23x0.9x
Tue, 22 Apr 2025€21.4b€20.1b€908.1m18.3x23.6x1.1x
Thu, 20 Mar 2025€23.0b€19.6b€796.9m21.2x28.8x1.2x
Sat, 15 Feb 2025€26.3b€20.0b€828.0m23.5x31.7x1.3x
Mon, 13 Jan 2025€24.9b€8.0b€834.7m22.1x29.8x3.1x
Wed, 11 Dec 2024€24.6b€19.0b€1.4b18.9x17.2x1.3x
Fri, 08 Nov 2024€25.0b€19.0b€1.4b16.3x18x1.3x
Sun, 06 Oct 2024€25.0b€18.9b€1.4b17.3x18.1x1.3x
Tue, 03 Sep 2024€25.8b€18.9b€1.4b15.1x18.6x1.4x
Thu, 01 Aug 2024€25.5b€18.9b€1.4b16.9x18.4x1.3x
Sat, 29 Jun 2024€25.6b€18.8b€1.4b16.4x18.5x1.4x
Mon, 27 May 2024€26.0b€18.8b€1.4b17.2x18.8x1.4x
Wed, 24 Apr 2024€26.3b€18.7b€1.4b19x19.1x1.4x
Fri, 22 Mar 2024€25.5b€18.6b€1.4b20.7x18.2x1.4x
Sun, 18 Feb 2024€25.2b€18.6b€1.4b18.6x18.1x1.4x
Tue, 16 Jan 2024€24.9b€18.6b€1.4b18.1x17.9x1.3x
Thu, 14 Dec 2023€24.0b€18.6b€1.4b18.2x17.2x1.3x
Sat, 11 Nov 2023€22.5b€18.6b€1.4b16.9x16.2x1.2x
Mon, 09 Oct 2023€22.7b€18.6b€1.4b16.5x15.7x1.2x
Wed, 06 Sep 2023€23.7b€17.3b€1.1b16.1x20.8x1.4x
Price to Earnings Ratio

20.8x


Total Market Cap: €23.7bTotal Earnings: €1.1bTotal Revenue: €17.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Italian Healthcare Sector Price to Earnings3Y Average 21.4x202420252026
Current Industry PE
  • Investors are relatively neutral on the Italian Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 21.4x.
  • The 3-year average PS ratio of 1.8x is lower than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have declined 19% per year.
  • This means that the cost of doing business could be reducing since sales have declined but profits have remained steady.

Industry Trends

Which industries have driven the changes within the Italian Healthcare sector?

IT Market0.038%
Healthcare0.61%
Life Sciences4.45%
Healthcare Services2.07%
Medical Equipment1.64%
Biotech-0.16%
Pharma-0.38%
Healthtech-1.14%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 32.6x.
    • Analysts are expecting annual earnings growth of 29.0%, which is higher than its past year's earnings decline of 21.2% per year.
  • Investors are most pessimistic about the Biotech industry, although it looks like investor sentiment has improved given that it's trading above its 3-year average.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 32% over the next 5 years.
  • This is better than its past earnings decline of 26% per year.
  • In contrast, the Biotech industry is expected to see its earnings decline by 104% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIA DiaSorin€76.622.0%
+€73.3m		-11.1%PE27x
AMP Amplifon€12.152.2%
+€69.1m		-22.0%PE44.6x
ELN EL.En€15.452.0%
+€24.8m		30.9%PE23.1x
FF Fine Foods & Pharmaceuticals N.T.M€8.924.4%
+€8.9m		2.8%PE30.5x
GHC Garofalo Health Care€5.661.1%
+€5.3m		17.2%PE23x

Latest News

REC
€52.65
Recordati Industria Chimica e Farmaceutica
7D
-0.4%
1Y
-0.2%
OPTS
€1.25
OPT
7D
17.9%
1Y
n/a
AMP
€12.15
Amplifon
7D
2.2%
1Y
-22.0%
Narrative Update • Aug 18

AMP: Vertical Integration Pivot And Equity Offering Will Pressure Future Returns

Analysts have raised Amplifon’s fair value estimate from €9.85 to €11.00, citing recent upgrades and higher price targets. They note that current valuations already factor in execution risks and indicate that there may be potential upside to earnings forecasts.
DIA
€76.62
DiaSorin
7D
2.0%
1Y
-11.1%
Narrative Update • Aug 07

DIA: Reset Expectations Will Support Upside As Sector Headwinds Ease

DiaSorin's updated analyst fair value estimate has moved from €81.30 to €90.00 as analysts weigh recent price target changes clustered around €60 and €76, taking into account revised assumptions for growth, margins, and future P/E multiples. Analyst Commentary Recent Street research on DiaSorin shows a split view, with some analysts cautious on execution risk and others more constructive on the company’s long term growth framework and valuation reset.
IVN
€1.48
iVision Tech
7D
4.6%
1Y
-31.5%
Analysis Article • Aug 07

Should You Think About Buying iVision Tech S.p.A. (BIT:IVN) Now?

While iVision Tech S.p.A. ( BIT:IVN ) might not have the largest market cap around , it saw significant share price...
GPI
€13.86
GPI
7D
-1.1%
1Y
-21.0%
PHIL
€23.40
Philogen
7D
-0.2%
1Y
-0.8%
Narrative Update • Jun 26

PHIL: Future Repricing Will Hinge On Lean Margins And Elevated P/E

Analysts have raised their price target on Philogen from €23.00 to about €27.67, citing updated fair value estimates, a slightly higher discount rate, and revised assumptions for revenue trends, profit margins, and future P/E levels. What’s in the News for Philogen No recent Philogen specific news items were identified in the provided sources.
ELN
€15.45
EL.En
7D
2.0%
1Y
30.9%
Narrative Update • Jun 25

ELN: Future Returns Will Rely On Margins And P E Assumptions

Analysts have lifted their price target for EL.En. from €11.00 to €16.00, citing updated assumptions around fair value, discount rate, revenue, profit margins and future P/E levels as key drivers of the change. What's in the News No recent company specific news items for EL.En. were identified in the provided sources.
OTO
€2.48
Otofarma
7D
-4.6%
1Y
-54.3%
SVS
€8.00
Svas Biosana
7D
-3.1%
1Y
-2.4%
GHC
€5.66
Garofalo Health Care
7D
1.1%
1Y
17.2%
Analysis Article • May 25

We Think Garofalo Health Care's (BIT:GHC) Healthy Earnings Might Be Conservative

Garofalo Health Care S.p.A.'s ( BIT:GHC ) solid earnings announcement recently didn't do much to the stock price. Our...
FF
€8.92
Fine Foods & Pharmaceuticals N.T.M
7D
4.4%
1Y
2.8%
Analysis Article • May 11

Analysts Are Updating Their Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) Estimates After Its First-Quarter Results

It's been a sad week for Fine Foods & Pharmaceuticals N.T.M. S.p.A. ( BIT:FF ), who've watched their investment drop...
EUK
€0.52
EuKedos
7D
3.0%
1Y
-27.8%